Latest Breaking News On - Brett whelan - Page 3 : comparemela.com

X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U S FDA for Mavorixafor in WHIM Syndrome

X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U S FDA for Mavorixafor in WHIM Syndrome
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPaula raganBrett whelanExchange commissionClinical immunology societyEuropean hematology associationPharmaceuticals nasdaqEuropean unionLifesci communicationsDrug administrationNew drug applicationUnited states foodChief executive officerBreakthrough therapy designationFast track designationRare pediatric designation

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - X4 Pharmaceuticals (NASDAQ:XFOR)

BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) X4 Pharmaceuticals (NASDAQ:XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system,

United statesBrett whelanChristophe arbet engelsLifesci communicationsPharmaceuticals incEquity incentive planChief medicalNasdaq listing rule

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq

BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule.

United statesBrett whelanChristophe arbet engelsPharmaceuticals incPharmaceuticals nasdaqLifesci communicationsEquity incentive planChief medicalNasdaq listing ruleNasdaq xforX4 pharmaceuticals

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesChristophe arbet engelsBrett whelanPharmaceuticals nasdaqLifesci communicationsPharmaceuticals incEquity incentive planChief medicalNasdaq listing rule

X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program

X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPaula raganChristophe arbet engelsBrett whelanCompany classEuropean hematology associationPharmaceuticals nasdaqExchange commissionManagement teamLifesci communicationsClinical immunology societyDevelopment rd expensesDrug applicationChief executive officerChief medical officerKey anticipated upcoming